Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification
暂无分享,去创建一个
Anne Vincent-Salomon | Salvatore Piscuoglio | Magali Lacroix-Triki | Larry Norton | Felipe C Geyer | Rachael Natrajan | Jorge S Reis-Filho | Laurent Arnould | J. Reis-Filho | L. Norton | A. Vincent-Salomon | B. Weigelt | F. Penault-Llorca | M. Lacroix-Triki | R. Natrajan | R. Lim | P. Cottu | X. Sastre-Garau | C. Ng | H. Wen | L. Arnould | L. Martelotto | F. Geyer | S. Piscuoglio | P. Wilkerson | Xavier Sastre-Garau | Britta Weigelt | Frederique Penault-Llorca | Charlotte KY Ng | Sylvia Giard | D. Rodrigues | Patty Wai | Luciano G Martelotto | C. Cowell | Daniel N Rodrigues | Paul H Cottu | Raymond S Lim | Arnaud Gauthier | Huei-Chi Wen | Catherine F Cowell | Paul M Wilkerson | Silvio E Bromberg | S. Bromberg | S. Giard | A. Gauthier | Patty T. Wai
[1] Christopher W. Wong,et al. RCP is a human breast cancer-promoting gene with Ras-activating function. , 2009, The Journal of clinical investigation.
[2] S. Gruber,et al. Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort , 2012, Breast Cancer Research and Treatment.
[3] I. Ellis,et al. Pathological prognostic factors in breast cancer. , 1999, Critical reviews in oncology/hematology.
[4] M. Moasser. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis , 2007, Oncogene.
[5] A. Vincent-Salomon,et al. Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] Alan Mackay,et al. FGFR1 Emerges as a Potential Therapeutic Target for Lobular Breast Carcinomas , 2006, Clinical Cancer Research.
[7] Daniel Birnbaum,et al. Prognosis and Gene Expression Profiling of 20q13-Amplified Breast Cancers , 2006, Clinical Cancer Research.
[8] R. Rodríguez-Barrueco,et al. Neuregulins and Cancer , 2008, Clinical Cancer Research.
[9] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[10] I. Ellis,et al. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.
[11] J. Reis-Filho,et al. Immunophenotypic and genomic characterization of papillary carcinomas of the breast , 2012, The Journal of pathology.
[12] James X. Sun,et al. Relapsed Classic E-Cadherin (CDH1)–Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 (ERBB2) Gene Mutations , 2013, Clinical Cancer Research.
[13] F. Markowetz,et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.
[14] Z. Szallasi,et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution , 2014, Science.
[15] Eunyoung Kang,et al. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance , 2012, Modern Pathology.
[16] S. Nofech-Mozes,et al. Intratumoral Heterogeneity of HER2/neu in Breast Cancer—A Rare Event , 2007, The breast journal.
[17] J. M. Lee,et al. eEF1A2 activates Akt and stimulates Akt-dependent actin remodeling, invasion and migration , 2007, Oncogene.
[18] Jayanta Debnath,et al. Modelling glandular epithelial cancers in three-dimensional cultures , 2005, Nature Reviews Cancer.
[19] 이연수. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer , 2011 .
[20] S. Biggins,et al. The Mub1/Ubr2 Ubiquitin Ligase Complex Regulates the Conserved Dsn1 Kinetochore Protein , 2013, PLoS genetics.
[21] F. Bertucci,et al. Comprehensive Profiling of 8p11-12 Amplification in Breast Cancer , 2005, Molecular Cancer Research.
[22] Marc K Halushka,et al. Intratumoral heterogeneity of HER-2 gene amplification and protein overexpression in breast cancer. , 2010, Human pathology.
[23] A. McKenna,et al. Absolute quantification of somatic DNA alterations in human cancer , 2012, Nature Biotechnology.
[24] S. Ethier,et al. Transforming properties of 8p11-12 amplified genes in human breast cancer. , 2010, Cancer research.
[25] A. Ashworth,et al. The genomic profile of HER2‐amplified breast cancers: the influence of ER status , 2008, The Journal of pathology.
[26] Calum MacAulay,et al. Integrative Genomic Analyses Identify BRF2 as a Novel Lineage-Specific Oncogene in Lung Squamous Cell Carcinoma , 2010, PLoS medicine.
[27] C. Swanton. Intratumor heterogeneity: evolution through space and time. , 2012, Cancer research.
[28] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.
[29] Li Ding,et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. , 2013, Cancer discovery.
[30] A. Ashworth,et al. Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast , 2014, The Journal of pathology.
[31] B. Weigelt,et al. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs , 2011, Oncogene.
[32] Wonshik Han,et al. CAMK1D amplification implicated in epithelial–mesenchymal transition in basal‐like breast cancer , 2008, Molecular oncology.
[33] J. Reis-Filho,et al. Getting it right: designing microarray (and not ‘microawry’) comparative genomic hybridization studies for cancer research , 2007, Laboratory Investigation.
[34] A. Børresen-Dale,et al. The Life History of 21 Breast Cancers , 2012, Cell.
[35] Javed Siddiqui,et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer , 2013, Nature Genetics.
[36] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[37] N. Turner,et al. Fibroblast growth factor signalling: from development to cancer , 2010, Nature Reviews Cancer.
[38] A. Ashworth,et al. DNA amplifications in breast cancer: genotypic-phenotypic correlations. , 2010, Future oncology.
[39] Yu Cao,et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing , 2014, Science.
[40] Nicolas Stransky,et al. Characterization of the recurrent 8p11-12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic target in breast cancer. , 2008, Cancer research.
[41] J. Reis-Filho,et al. Epistatic interactions and drug response , 2014, The Journal of pathology.
[42] Li Ding,et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. , 2013, Cell reports.
[43] Robert D. Cardiff,et al. Insights from transgenic mouse models of ERBB2-induced breast cancer , 2007, Nature Reviews Cancer.
[44] Carlos Caldas,et al. ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium , 2011, EMBO molecular medicine.
[45] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[46] Hanna Göransson,et al. Screening for copy‐number alterations and loss of heterozygosity in chronic lymphocytic leukemia—A comparative study of four differently designed, high resolution microarray platforms , 2008, Genes, chromosomes & cancer.
[47] M. Scaltriti,et al. Biomarkers of drugs targeting HER‐family signalling in cancer , 2014, The Journal of pathology.
[48] J. Reis-Filho,et al. Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra‐tumour genetic heterogeneity and clonal selection , 2012, The Journal of pathology.
[49] Mitch Dowsett,et al. HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity , 2014, Modern Pathology.
[50] M. Bissell,et al. FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice. , 2012, The Journal of clinical investigation.
[51] J. Troge,et al. Tumour evolution inferred by single-cell sequencing , 2011, Nature.
[52] J. Troge,et al. Inferring tumor progression from genomic heterogeneity. , 2010, Genome research.
[53] Simion I. Chiosea,et al. Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands , 2014, Nature Genetics.
[54] John M S Bartlett,et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.
[55] A. Ashworth,et al. Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas , 2010, The Journal of pathology.
[56] B. Coe,et al. Resolving the resolution of array CGH. , 2007, Genomics.
[57] Judith Abrams,et al. Multiple interacting oncogenes on the 8p11-p12 amplicon in human breast cancer. , 2006, Cancer research.
[58] J. Zidan,et al. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease , 2005, British Journal of Cancer.
[59] Aleix Prat Aparicio. Comprehensive molecular portraits of human breast tumours , 2012 .
[60] Irmtraud M. Meyer,et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.
[61] David Chen,et al. ESR1 ligand binding domain mutations in hormone-resistant breast cancer , 2013, Nature Genetics.
[62] T. Hubbard,et al. A census of human cancer genes , 2004, Nature Reviews Cancer.
[63] N. Navin,et al. Clonal Evolution in Breast Cancer Revealed by Single Nucleus Genome Sequencing , 2014, Nature.
[64] Kristian Helin,et al. Amplification of Mdmx (or Mdm4) Directly Contributes to Tumor Formation by Inhibiting p53 Tumor Suppressor Activity , 2004, Molecular and Cellular Biology.
[65] C. Perou,et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[66] M. Dowsett,et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.